- Home
- HITI vs MOLN Comparison
HITI vs MOLN Comparison
Compare HITI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HITI
- MOLN
- Stock Information
- Founded
- HITI 2009
- MOLN 2004
- Country
- HITI Canada
- MOLN Switzerland
- Employees
- HITI N/A
- MOLN N/A
- Industry
- HITI
- MOLN
- Sector
- HITI
- MOLN
- Exchange
- HITI Nasdaq
- MOLN Nasdaq
- Market Cap
- HITI 249.3M
- MOLN 195.4M
- IPO Year
- HITI N/A
- MOLN 2021
- Fundamental
- Price
- HITI $3.00
- MOLN $5.30
- Analyst Decision
- HITI Strong Buy
- MOLN
- Analyst Count
- HITI 1
- MOLN 0
- Target Price
- HITI $4.50
- MOLN N/A
- AVG Volume (30 Days)
- HITI 620.1K
- MOLN 7.1K
- Earning Date
- HITI 03-14-2025
- MOLN 03-13-2025
- Dividend Yield
- HITI N/A
- MOLN N/A
- EPS Growth
- HITI N/A
- MOLN N/A
- EPS
- HITI N/A
- MOLN N/A
- Revenue
- HITI $370,017,302.00
- MOLN $7,105,397.00
- Revenue This Year
- HITI $7.52
- MOLN N/A
- Revenue Next Year
- HITI $14.03
- MOLN $29.41
- P/E Ratio
- HITI N/A
- MOLN N/A
- Revenue Growth
- HITI 9.02
- MOLN N/A
- 52 Week Low
- HITI $1.57
- MOLN $3.32
- 52 Week High
- HITI $3.62
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- HITI 44.45
- MOLN 48.54
- Support Level
- HITI $3.01
- MOLN $4.98
- Resistance Level
- HITI $3.16
- MOLN $5.91
- Average True Range (ATR)
- HITI 0.15
- MOLN 0.27
- MACD
- HITI -0.03
- MOLN 0.05
- Stochastic Oscillator
- HITI 16.07
- MOLN 47.50
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker's Corner Ltd., Grasscity.com, Canna Cabana Inc., and KushBar Inc. The firm has established two main segments, retail and wholesale. It generates substantial revenue from retail stores' e-commerce platforms. Geographically it serves Canada, the USA, and other international markets and earns key revenue from domestic sales.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.